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Strong experimental evidence in animal and cellular models supports a piv-
otal role of sphingosine kinase-1 (SK1) in oncogenesis. In many human
cancers, SK1 levels are upregulated and these increases are linked to poor
prognosis in patients. Here, by employing untargeted NMR-based metabo-
lomic profiling combined with functional validations, we report the crucial
role of SK1 in the metabolic shift known as the Warburg effect in A2780
ovarian cancer cells. Indeed, expression of SK1 induced a high glycolytic
rate, characterized by increased levels of lactate along with increased
expression of the proton/monocarboxylate symporter MCT1, and
decreased oxidative metabolism, associated with the accumulation of inter-
mediates of the tricarboxylic acid cycle and reduction in CO2 production.
Additionally, SK1-expressing cells displayed a significant increase in glu-
cose uptake paralleled by GLUT3 transporter upregulation. The role of
SK1 is not limited to the induction of aerobic glycolysis, affecting meta-
bolic pathways that appear to support the biosynthesis of macromolecules.
These findings highlight the role of SK1 signaling axis in cancer metabolic
reprogramming, pointing out innovative strategies for cancer therapies.
1. Introduction
Sphingosine kinase (SK) catalyzes the ATP-dependent
phosphorylation of sphingosine (Sph) leading to the
production of the bioactive sphingolipid sphingosine 1-
phosphate (S1P) (Pyne et al., 2016). Two different iso-
forms of SK do exist, SK1 and SK2 that, although
both contribute to intracellular S1P formation, have
been found to display opposite biological roles due to
their different subcellular localization and regulation
(Maceyka et al., 2005). Strong experimental evidence
in animal and cellular models supports the involve-
ment of SK1 in oncogenesis (Heffernan-Stroud and
Obeid, 2013): this enzyme plays important roles in
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most tumorigenic processes being required for the pro-
motion of survival (Vadas et al., 2008), proliferation
(Sukocheva et al., 2006), transformation (Xia et al.,
2000) as well as neoangiogenesis, which ensures tumor
growth (LaMontagne et al., 2006).
In many human cancers such as breast, ovary, pros-
tate, and lung cancer, SK1 levels are upregulated
(Akao et al., 2006; Johnson et al., 2005; Ruckhaberle
et al., 2008; Sutphen et al., 2004), and these increases
are linked to poor prognosis in patients (Kim et al.,
2015; Ruckhaberle et al., 2008; Van Brocklyn et al.,
2005). Fifteen years ago, the oncogenic potential of
SK1 was proposed (Xia et al., 2002); however so far,
no mutations on Sphk1 gene have been identified in
human tumors (Vadas et al., 2008). The reliance of
cancer cells on SK1 signaling pathway, which becomes
overexpressed without any evident mutations, is called
nononcogene addition (Vadas et al., 2008). The exact
molecular mechanisms that lead to the addition of
cancer cells to SK1 signaling pathway and the precise
mechanism of action of SK1 in cancer development
remain to be elucidated.
Elevated levels of SK1 have also been shown to con-
tribute to pancreatic cancer cell resistance to gemc-
itabine and chronic myeloid leukemia resistance to
imatinib (Pyne et al., 2011). In this regard, we reported
that in A2780 human ovarian carcinoma cells resistant
to the synthetic retinoid N-(4-hydroxyphenyl) reti-
namide (HPR) SK1 activity, mRNA and protein levels
were increased and treatment with an SK inhibitor
resulted in increased sensitivity to HPR (Illuzzi et al.,
2010). Moreover, the overexpression of SK1 in A2780
cells was sufficient to induce resistance to HPR, demon-
strating the key role of SK1 in determining the resis-
tance to the chemotherapeutic drug (Illuzzi et al., 2010).
The catabolism of the bioactive lipid S1P is under the
control of different enzymes: S1P can be irreversibly
degraded by S1P lyase (SPL) or reversibly dephospho-
rylated to Sph by two distinct specific S1P phosphatases
(SPP), which can be then acylated to ceramide (Cer) in
the sphingolipid salvage pathway (Maceyka et al.,
2012). Cer and S1P are interconvertible lipids, and it
has been proposed that their relative intracellular levels
dictate the cell fate. Indeed, according to the so-called
sphingolipid rheostat, shifting the equilibrium toward
S1P induces survival, while Cer increases apoptosis
(Newton et al., 2015). S1P can be exported outside the
cells and becomes the ligand, in an autocrine/paracrine
manner, of a family of G protein-coupled receptors
named S1P receptors (S1PR), S1P1-5, which mediate the
majority of S1P effects (Blaho and Hla, 2014).
The metabolic characteristics of cancer cells are pro-
foundly different from those of normal cells. Cancer
cells are dependent on aerobic glycolysis, a metabolic
feature known as Warburg effect, that explains how
faster glycolytic breakdown is preferred to mitochon-
drial oxidative phosphorylation for energy production
(Vander Heiden et al., 2009). Moreover, it is supposed
that this cancer-related metabolic adaptation is neces-
sary to facilitate the incorporation of nutrients such as
nucleotides, amino acids, and lipids into the biomass
required for enhanced cancer cell proliferation (Hsu
and Sabatini, 2008). This metabolic cancer reprogram-
ming has been linked also to therapeutic resistance in
cancer (Zhou et al., 2010). Indeed, targeting cancer cell
metabolism in combination with chemotherapeutic
drugs may represent a promising approach to inhibit
cancer growth and overcome drug resistance. How-
ever, a better understanding of the molecular mecha-
nisms and cellular targets that link metabolic
regulation with signaling pathways involved in the
modulation of survival, proliferation, and drug resis-
tance of cancer cells is required.
Here, by employing an untargeted NMR metabolo-
mic profiling combined with functional validations, we
show for the first time that SK1 plays a crucial role in
the metabolic reprogramming of A2780 human ovarian
cancer cells. Indeed, stable overexpression of SK1
induced high glycolytic rate, with increased glucose
uptake and augmented levels of lactate, and decreased
oxidative metabolism, associated with accumulation of
intermediates of the tricarboxylic acid cycle (TCA) and
reduction in CO2 production. Furthermore, the reported
data show that the role of SK1 is not restricted to the
aerobic glycolysis switch, affecting metabolic pathways
that may support synthesis of macromolecules.
These results point out novel molecular mechanisms
for cancer development and progression and potential
innovative strategies in cancer therapy.
2. Materials and methods
2.1. Cell culture and transfection
Cells were cultured in RPMI 1640 supplemented with
10% of heat-inactivated fetal bovine serum, 2 mM glu-
tamine, 100 unitsmL1 penicillin, and 100 lgmL1
streptomycin. A2780 cells were transfected by
FuGENE (Roche Applied Science, Mannheim, Ger-
many) with the pcDNA3-hSK1WTFLAG (Pitson et al.,
2000) (a gift from Stuart M. Pitson, Centre for Cancer
Biology, Adelaide, Australia) or with the empty vector,
following the manufacturer’s protocol. A mixed popu-
lation of transfected drug-resistant cells were isolated
after selection with 500 lgmL1 geneticin (Sigma-
Aldrich, St. Louis, MO, USA) for three weeks. Under
518 Molecular Oncology 11 (2017) 517–533 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
SK1 determines the metabolic phenotype in cancer C. Bernacchioni et al.
these selective conditions, a polyclonal population of
stably expressing cells was obtained. The selected
stable transfectants were then cultured in the presence
of 250 lgmL1 geneticin.
2.2. NMR sample preparation
Four independent experiments were performed. In each
experiment, mock- and SK1-expressing cells were plated
and grown until subconfluence. The media of two sub-
confluent p100 were replenished with fresh media (FBS:
growing condition; without FBS: serum starvation con-
dition) for 24 h prior to cell harvesting. This allowed for
standardization of the time between equilibration of
extra- and intracellular metabolites and reduced the
effects of substrate limitation on the intracellular meta-
bolism. Metabolomic studies were performed in growing
cells and in serum-starved cells (RPMI 1640 supple-
mented with 1 mgmL1 BSA, 2 mM glutamine,
100 unitsmL1 penicillin, and 100 lgmL1 strepto-
mycin). After 24 h, the media were removed and the
cells washed twice with ice-cold PBS, dispersed in a buf-
fer solution containing 10 mM Tris pH 7.4, 5 mM
EDTA, 120 mM NaCl, protease inhibitor [1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 0.3 lM aprotinin,
10 lgmL1 leupeptin, and 10 lgmL1 pepstatin], and
phosphatase inhibitors (Phosphatase Inhibitor Cocktail
3; Sigma-Aldrich). Cell lysis was performed by sonica-
tion and the cytosolic fraction containing the metabo-
lites was obtained as previously described (Bernacchioni
et al., 2012; Cencetti et al., 2010, 2013).
From each of the four independent experiments, we
obtained four samples: mock growing; SK1 growing;
mock serum-starved; and SK1 serum-starved. NMR
samples were prepared in 5.00 mm NMR tubes (Bruker
BioSpin srl, Rheinstetten, Germany) after the addition
of 50 lL of 2H2O containing 10 mM sodium trimethylsi-
lyl [2,2,3,3-2H4]propionate to 450 lL of cell lysate.
2.3. Cell treatment
Three to five independent experiments were performed
for each treatment reported below.
In order to investigate the effect of exogenously
added S1P on A2780 cell metabolism, subconfluent
mock cells were treated with 1 lM S1P for 24 h under
serum starvation.
To evaluate the involvement of S1P3 in the meta-
bolic shift induced by SK1 or the effect of SK1 inhibi-
tion, subconfluent SK1-expressing cells were treated
under serum starvation with the S1P1/3 antagonist
VPC23019 (1 lM) for 24 h or the SK1-specific inhibi-
tor VPC96091 (5 lM) for 24 h, respectively.
2.4. NMR experiments
1H NMR spectra were acquired on cell lysates verifying
their feasibility and reproducibility (Fig. S1). NMR
spectra were recorded with a Bruker 900-MHz spec-
trometer equipped with CP TCI 1H/13C/15N probe. 1H
NMR spectra were acquired with the Carr–Purcell–
Meiboom–Gill (CPMG) sequence using a monodimen-
sional spin–echo sequence with water presaturation
(cpmgpr; Bruker BioSpin srl); 128 scans over a spectral
region of 18 kHz were collected into 110 K points, giv-
ing an acquisition time of 3.07 s. The CPMG pulse
sequence (Carr and Purcell, 1954) was used to impose a
T2 filter that allows selective observation of small
molecular weight components. The total T2 delay was
set to 290 ms. The T2 filtering in the CPMG pulse
sequence, which contains trains of -(s-180°-s)- blocks
repeated n = 128 times, was achieved with a total spin
echo delay (2ns) of 80 ms. The acquisition of each spec-
trum required about 16 min. The raw data were multi-
plied by a 1-Hz exponential line broadening before
Fourier transformation into 131 K points. Transformed
spectra were automatically corrected for phase and
baseline distortions and calibrated (chemical shift was
referenced to the proton of alanine at d 1.48 p.p.m.)
using TopSpin 3.5 (Bruker BioSpin srl). We successfully
performed this type of experiments on samples obtained
from independent experiments identifying the metabo-
lomic fingerprint of A2780 parental cells and of their
derivative A2780 cells overexpressing SK1, as well as of
cells treated with S1P, VPC96091, and VPC23019.
2.5. Spectral analysis
Each spectrum in the region 10.00–0.2 p.p.m. was seg-
mented into 0.02 p.p.m. chemical shift bins, and the cor-
responding spectral areas were integrated using the AMIX
software (Bruker BioSpin srl). The area of each bin was
normalized to the total spectral area (Craig et al., 2006;
Smolinska et al., 2012), calculated with exclusion of the
regions 2.60–2.83, 3.23–3.28, 3.35–3.39, 3.63–3.75, 6.45–
6.49, 7.30–7.36, 8.44–8.48 (which correspond to EDTA
peaks and the most intense peaks of the protease and
phosphatase inhibitors used for sample preparation)
and 4.2–5.9 p.p.m. (water region).
2.6. Metabolite statistical analysis
Various kinds of multivariate and univariate statistical
techniques were applied on the obtained buckets using
R 3.0.2 in house scripts.
Unsupervised principal component analysis (PCA)
was used to obtain a preliminary outlook of the data
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(visualization in a reduced space, clusters detection,
screening for outliers). From the PCA score plot (PC1,
PC2, PC3), Fig. S2, a perfect discrimination between
the two different conditions tested (growing and serum
starvation) was clearly visible, indicating a strong
influence on the cell metabolic profiles; nevertheless, a
great discrimination between mock cells and SK1-
expressing cells was clearly visible in both conditions
tested. Partial least squares (PLS) was employed to
perform supervised data reduction and classification
between growing and the serum starvation condition.
In order to analyze the difference in the metabolic fin-
gerprint induced by SK1 expression, multilevel partial
least squares (M-PLS) was employed to perform super-
vised data reduction and classification. With this
approach, within each independent experiment, for a
specific experimental condition, mock- and SK1-
expressing cells can be considered as paired control
and treated samples, thus allowing the reduction in the
experimental variability between independent cell cul-
ture experiments and the metabolic variability intro-
duced by the media composition (van Velzen et al.,
2008; Westerhuis et al., 2010). The global accuracy for
classification was assessed by means of a leave-one-out
cross-validation scheme.
Thirty-two metabolites, whose peaks in the spectra
were well defined and resolved, were assigned and their
levels analyzed (Table S1), after total area normaliza-
tion calculated as described in Section 2.4. The assign-
ment procedure was performed using a NMR spectra
library of pure organic compounds, public databases
(e.g., Human Metabolome Database), storing reference
NMR spectra of metabolites, spiking NMR experi-
ments, and using literature data. The relative concen-
trations of the various metabolites were calculated by
integrating the corresponding signals in the spectra
(Wishart, 2008). The paired Wilcoxon test was used
for the determination of the meaningful metabolites: a
P-value of 0.05 was considered statistically significant.
The concentration changes in the metabolites are also
expressed as the log2(FC) (fold change; Fig. S3).
2.7. Sphingolipid mass spectrometry (MS)
Sph and S1P were extracted as recently described
(Japtok et al., 2015; Pewzner-Jung et al., 2014) using
D7-S1P and D7-Sph as internal standards. Sphin-
golipids were separated by reverse-phase high-perfor-
mance liquid chromatography (HPLC) (Agilent 1290
series; Agilent Technologies, Waldbronn, Germany)
using a ZORBAX Eclipse Plus C8 column
(2.1 9 150 mm, ID: 3.5 lm) (Agilent Technologies).
Solvent A was 50 : 50 methanol/acetonitrile with 0.1%
formic acid and solvent B was water with 0.1% formic
acid. The gradient was held at 60% A between 0 and
3 min, increased linearly from 60% A to 84% A
between 3 min and 11 min, returned linearly to 60%
A and held for 3 min to allow column re-equilibration.
The flow rate was 0.5 mLmin1. The injection volume
was 10 lL. The HPLC column effluent was introduced
onto a QQQ 6490 mass spectrometer (Agilent Tech-
nologies) operating in the positive ESI mode. Capillary
and V charging were 4.5 and 2 kV, respectively. Dry-
ing gas temperature was 290 °C, drying gas flow rate
was 11 Lmin1, sheath gas temperature was 380 °C,
sheath gas flow rate was 12 Lmin1, and nebulizer
pressure was 35 psi. The precursor ion of Sph m/z
300.29 was cleaved into the fragment ion of m/z 282.3
at 8 eV; the precursor ion of D7-Sph m/z 307.3 was
cleaved into the fragment ion of m/z 289.3 at 8 eV.
The precursor of S1P m/z 380.26 was cleaved into the
fragment ion of m/z 264.3 at 16 eV. The precursor of
D7-S1P m/z 387.3 was cleaved into the fragment ion
of m/z 271.3 at 16 eV. Ceramides were extracted and
quantified as recently described (Huston et al., 2016).
Briefly, lipid extraction was performed using C17-Cer
as internal standard. Sample analysis was carried out
by HPLC-MS/MS using a Q-TOF 6530 mass
spectrometer (Agilent Technologies) operating in the
positive ESI mode. The precursor ions of ceramides
(C16-Cer (m/z 520.508), C17-Cer (m/z 534.524), C18-
Cer (m/z 548.540), C20-Cer (m/z 576.571), C22-Cer
(m/z 604.602), C24-Cer (m/z 632.634), C24:1-Cer (m/z
630.618)) were cleaved into the fragment ion of
m/z 264.270. Quantification was performed with MASS
HUNTER Software (Agilent Technologies).
2.8. Glucose uptake
Glucose uptake was evaluated in a buffered solution
(140 mM NaCl, 20 mM Hepes/Na, 2.5 mM MgSO4,
1 mM CaCl2, and 5 mM KCl, pH 7.4) containing
0.5 lCimL1 [U-14C] glucose (Perkin Elmer, Wal-
tham, MA, USA) for 15 min at 37 °C. Cells were sub-
sequently washed with cold PBS and lysed with 0.1 M
NaOH. Incorporated radioactivity was assayed by liq-
uid scintillation counting and normalized on protein
content as previously described (Rapizzi et al., 2009).
2.9. Detection of released CO2 by radioactive
glucose
A2780 cells were added with 0.5 lCimL1 [U-14C] glu-
cose (Perkin Elmer) for 15 min. Each dish had a taped
piece of Whatman paper facing the inside of the dish
wetted with 100 lL of phenyl-ethylamine/methanol
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(1 : 1) to trap CO2. Then, 200 lL of 4 M H2SO4 was
added to cells. Whatman paper was removed and trans-
ferred to scintillation vials for counting. Radioactive
signal was measured by liquid scintillation counting and
normalized for protein content.
2.10. Quantitative real-time reverse transcription
PCR
Total RNA (2 lg), extracted with TRI reagent from
A2780 cells, was reverse-transcribed using the high-
capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA). The quantification
of S1P metabolism enzymes (SK1, SK2, SPL, SPP1,
and SPP2) and S1PR mRNA was performed by real-
time PCR employing TaqMan gene expression assays.
Each measurement was taken in triplicate, using the
automated ABI Prism 7500 Sequence Detector System
(Applied Biosystems) as described previously (Cencetti
et al., 2013; Donati et al., 2011), by simultaneous
amplification of the target sequence together with the
housekeeping gene b-actin. Results were analyzed by
ABI Prism SEQUENCE DETECTION SYSTEM software, ver-
sion 1.7 (Applied Biosystems). The 2DDCT method
was applied as a comparative method of quantification
(Livak and Schmittgen, 2001), and data were normal-
ized to b-actin RNA expression.
2.11. Western blot analysis
A2780 cells lysates were obtained as described in the
NMR sample preparation section. Proteins from cell
lysates were resuspended in Laemmli’s SDS sample
buffer. Samples were subjected to SDS/PAGE and
western blot analysis. Bound antibodies were detected
using ECL reagents (Bernacchioni et al., 2011; Gan-
goiti et al., 2012). The intensities of the detected speci-
fic bands were normalized on the band intensities of
the loading controls (b-actin or total ERK or total
Akt), and the resulted data were reported as
mean  SEM, -fold change over control set as 1.
3. Results and Discussion
3.1. Study design
Our previous results demonstrated that SK1 expression
in A2780 human ovarian cancer cells is sufficient to
induce resistance to the chemotherapeutic agent HPR
(Illuzzi et al., 2010). To understand the cellular pro-
cesses induced by SK1 expression, here we focused on
SK1 regulation of cancer cell metabolism. The experi-
mental plan involved two different conditions: (i) the
growing condition, in order to characterize the differ-
ences induced by SK1 expression in ovarian cancer
cells, and (ii) the serum starvation condition, to mark
out the effect of SK1 expression in the absence of
mitogens. In order to study the metabolic phenotype,
we propose a multidisciplinary approach based on
matching molecular/cellular biology methods with
NMR-based metabolomics, an untargeted method to
determine the overall intracellular metabolite composi-
tion pool, readout of any metabolic activity, called
metabolome.
3.2. SK1 expression in ovarian cancer cells affects
the metabolomic profiles
In order to study the possible metabolomic changes
induced by SK1 expression, 1H-NMR spectra were
acquired (Fig. S1) using a high-field 900-MHz spec-
trometer equipped with cryoprobe. From the acquired
NMR profiles of growing and serum-starved A2780
cells, it emerges that there are obvious differences (at-
tributable to metabolic depression under starvation),
which can be discriminated at the level of unsupervised
PCA (Fig. S2), and have a discrimination accuracy of
100% using a PLS supervised approach. Nevertheless,
we could successfully identify the metabolomic finger-
print of A2780 ovarian cancer parental cells as well as
their derivative overexpressing SK1, independently on
the growing conditions. Using an NMR-untargeted
approach, we demonstrated that SK1 expression is suf-
ficient to alter radically the metabolomic profile of
ovarian cancer cells (Fig. 1A), with a discrimination
accuracy of 100% between SK1-expressing A2780 and
control mock cells when a M-PLS statistical analysis
was applied.
Stable overexpression of SK1 in A2780 human ovar-
ian cells was verified through mRNA relative quantifi-
cation by real-time RT-PCR analysis and by
measuring protein expression levels through western
blotting (WB) (Fig. 1B). Consistently, S1P levels, as
measured by MS, increased significantly in both lysates
and media of SK1-expressing cells with respect to
mock control cells (Fig. 1C). In accordance, we
observed a significant decrease in Sph levels, while no
significant changes were observed in terms of Cer
levels (Fig. S4). We then determined whether other
S1P-metabolizing enzymes were altered because of
SK1 expression. No compensatory alterations on the
expression levels of SK2 occurred, as shown by real-
time RT-PCR analysis (Fig. 1D) and WB (Fig. 1E).
Accordingly, the involvement of SK2 isoform in the
metabolic shift toward aerobic glycolysis was also
excluded in a previous report: by employing SK
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inhibitors and a LC/MS approach, Watson and collab-
orators reported that while SK1 induces the Warburg
effect on androgen-sensitive LNCaP prostate cancer
cells, SK2 exhibits a nonoverlapping function (Watson
et al., 2013).
It has been proposed that loss of the expression of
SPL, the enzyme that irreversibly degrades S1P, might
contribute to tumorigenesis (Bandhuvula and Saba,
2007). Here, we analyze the effect of SK1 on the
expression of SPL and S1P phosphatases in A2780
ovarian cancer cells. SPL mRNA and protein levels
were not altered by SK1 expression as demonstrated
by real-time RT-PCR analysis (Fig. 1D) and WB
(Fig. 1E). Moreover, real-time RT-PCR analysis
showed that the expression of SPP1 and SPP2, the
specific S1P phosphatases, was not altered (Fig. 1D):
SPP1 was not affected consequently to SK1 expres-
sion, whereas the expression of SPP2 was not detect-
able either in control or in SK1-overexpressing A2780
ovarian cancer cells. Thus, it appears that enhanced
SK1 expression did not overtly affect the other S1P-
metabolizing enzymes.
3.3. SK1 induces the Warburg effect in ovarian
cancer cells
Metabolomic profiles here analyzed provided steady-
state levels of metabolites, resulting from the balance
between production and consumption of each mole-
cule. The comparison of the metabolic profiles charac-
teristic of SK1-expressing ovarian cancer cells with
those of parental cells led to the identification of
SK1-dependent significant changes in the cell metabo-
lome. The main metabolites responsible for the
discrimination are related to the glycolytic pathway.
In SK1-expressing cells, a significant decrease in glu-
cose 6-phosphate levels was accompanied by a marked
increase in lactate levels (Fig. 2A), suggesting the
occurrence of SK1-induced Warburg effect. Consis-
tently, the SK1-expressing cells showed a 20% increase
in the uptake of radioactive glucose (Fig. 2B). There-
fore, the higher amount of uptaken glucose (Fig. 2B)
is metabolized faster in SK1-expressing ovarian cancer
cells leading to lower intracellular glucose 6-phosphate
levels (Fig. 2A). Hence, SK1-expressing ovarian cancer
cells show accelerated glycolytic metabolism and high
glucose requirements. The upregulation of specific glu-
cose transporters, especially the GLUT1 and GLUT3
proteins, is reported as a key mechanism by which
malignant cells achieve increased glucose uptake to
support their high rate of glycolysis (Szablewski,
2013). Thus, we analyzed the expression of the glucose
transporters GLUT1 and GLUT3 by WB, demon-
strating that in SK1-expressing cells GLUT3 is upreg-
ulated, while GLUT1 expression is unaffected
(Fig. 2C). These results demonstrated that the
increased glucose uptake positively correlates with an
enhanced expression of GLUT3, suggesting the
involvement of this low KM transporter isoform in
glucose internalization. Accordingly, GLUT3 has been
found overexpressed in different types of cancer (Sza-
blewski, 2013), including ovarian cancer (Younes
et al., 1997).
The analysis of other metabolites directly or indi-
rectly produced by the glycolytic pathway provided
some hints on the overall process. The pyruvate levels
were not significantly affected by SK1 expression.
Although efficient glycolysis obviously produced high
amount of pyruvate, this molecule is also the substrate
of a number of biochemical processes that maintains
its steady-state levels unaffected. Indeed, besides being
reduced to lactate, pyruvate can be transaminated to
produce alanine, whose levels were also increased in
SK1-expressing metabolomic NMR profiles (Fig. 2A).
Fig. 1. SK1 overexpression in A2780 ovarian cancer cells. (A) Score plot of multilevel PLS discrimination of metabolomics profiles of mock-
(blue dots) and SK1- (red dots) cell lysates. The plot was constructed using 1H-NMR CPMG spectra. Right panel: cross-validation paired test
and confusion matrix for mock and SK1 samples; sensitivity of the test = 100%; specificity of the test = 100%. (B) Overexpression of SK1
tagged with FLAG M2 epitope. Left panel: quantitative analysis of SK1 mRNA by real-time RT-PCR as fold changes according to the 2ΔΔCT
method. Data are reported as mean  SEM of three independent experiments. The overexpression of SK1 in pcDNA3-hSK1WT-transfected
compared to empty vector-transfected cells was statistically significant by Student’s t-test, *P < 0.05. Central and right panels: SK1-FLAG
expression levels in stably transfected A2780 cells by WB analysis using specific monoclonal anti-SK1 (central panel) and anti-FLAG (right
panel) antibodies. Equally loaded protein was checked by expression of b-isoform of actin. (C) Mock- and SK1-expressing cells were serum-
starved for 24 h before the media were collected (left panel) and cells harvested (right panel) and then subjected to S1P analysis. The effect
of SK1 expression on S1P levels in the media and inside the cells was statistically significant by Student’s t-test *P < 0.05. (D) Quantitative
mRNA analysis by real-time PCR in total extracted RNA. SK2, SPL, SPP1, and SPP2 mRNA quantitation was based on the 2ΔΔCT method,
using SK2, SPL, or SPP1 of the mock-transfected specimen as calibrator. Data are the mean  SEM of three experiments performed in
triplicate. nd, not detected. (E) SK2 and SPL expression by WB analysis. Equally loaded protein was checked by expression of b-isoform of
actin. A blot representative of three independent experiments with analogous results is shown. Bar plots represent the densitometric
analysis of at least three independent experiments. Data are the mean  SEM and are reported as protein expression normalized to b-actin,
-fold change over control set as 1.
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A significant portion of glycolytic carbon can be
diverted toward serine and glycine biosynthesis by
phosphoglycerate dehydrogenase. Consistently, glycine
levels were also increased (Fig. 2A). Altogether, these
results demonstrate that SK1 expression induces a sig-
nificant increase in glycolysis under aerobic conditions.
The glycolytic phenotype results in increased lactate
production. Consequently, to prevent cellular acidosis,
tumor cells display an increased expression of the pro-
ton/monocarboxylate symporters MCT. Because of the
relevance of MCT1 and/or MCT4 as hallmarks of sev-
eral human malignancies (Halestrap and Meredith,
2004; Halestrap and Wilson, 2012), here we evaluated
their expression levels by WB. As shown in Fig. 2D,
SK1-expressing ovarian cancer cells displayed a signifi-
cant increase in MCT1 while MCT4 was downregu-
lated, suggesting a major role for MCT1 in driving the
efflux of proton/lactate in these cells. Accordingly,
MCT1 recently emerged as a key promoter of drug
resistance in ovarian cancer by antagonizing Fas (Yan
et al., 2015). Moreover, MCT1 strongly increased in
both cisplatin-resistant ovarian cancer tissue and cell
lines compared with sensitive ovarian cancer tissue and
cells, respectively. Furthermore, in gastric cancer, a
significant downregulation of MCT4 has been corre-
lated with the malignant progression (Pinheiro et al.,
2009).
3.4. SK1 affects the tricarboxylic acid cycle (TCA)
Untargeted metabolomic profiles also highlighted a
significant increase in the intracellular levels of citrate,
succinate, fumarate, and malate in SK1-expressing
cells under aerobic condition (Fig. 3A). Consistently,
SK1-expressing cells displayed a significant reduction
in CO2 production (Fig. 3B).
These results suggest that SK1 expression altered
the TCA cycle with consequent accumulation of reac-
tion intermediates. The strong increase in these
intermediate levels could be, at least partially, ascribed
to feeding pathways. Accordingly, the here observed
SK1-induced significant reduction in the essential
amino acid valine (Fig. 3A) can be tentatively ascribed
to an enhanced valine catabolism brought about to
support the TCA cycle at the level of succinate via
propionyl-CoA and succinyl-CoA formation; neverthe-
less, the quantification of more intermediates would be
necessary to confirm the involvement of this pathway.
Notably, it has been recently proposed that fumarate
and succinate behave as oncometabolites that, upon
accumulation, become responsible for different malig-
nant-associated states (Yang et al., 2013).
From the NMR profiles, we measured an SK1-
induced increase in the levels of arginine (Fig. 3A), a
semi-essential amino acid (Appleton, 2002) critical for
the growth of human cancers. The de novo synthesis of
arginine relies on the enzyme argininosuccinate syn-
thase, expressed in ovarian cancer (Nicholson et al.,
2009), that leads to the formation of arginine and
fumarate, one of the TCA intermediates found aug-
mented consequently to SK1 expression (Fig. 3A). It is
interesting to note that the increase in arginine levels is
relevant per se because, besides being used for protein
synthesis, this amino acid is involved in multiple
aspects of tumor metabolism, including the synthesis
of nitric oxide, polyamines, nucleotides, proline, and
glutamate (Delage et al., 2010).
In order to further underline the specificity of the
metabolic changes caused by SK1 activity, SK1-expres-
sing A2780 cells were treated with a specific SK1 inhi-
bitor before being processed for the NMR-based
metabolomic analysis. The metabolic profiles obtained
from SK1-expressing A2780 cells incubated with the
SK1-specific inhibitor VPC96091 (5 lM for 24 h)
showed that the changes in glycolytic and TCA
metabolite levels induced by SK1 expression were
strongly reduced by SK1 inhibition (Fig. S5). In sum-
mary, these data definitely demonstrate that increased
Fig. 2. SK1 expression induces a glycolytic switch in A2780 ovarian cancer cells. A2780 mock and SK1 cells were cultured in growing
medium or serum-starved for 24 h. (A) Box plots: the relative concentration levels of the indicated metabolites in each group were
calculated by integrating the signal area in the respective 1H-NMR spectra. Changes in metabolite levels caused by SK1 overexpression
were statistically significant by paired Wilcoxon test, *P < 0.05. (B) [14C]-glucose uptake normalized on protein content. The increase in
glucose uptake induced by SK1 expression was statistically significant by Student’s t-test, *P < 0.05. (C) Expression levels of GLUT1 and
GLUT3 transporters by WB. Equally loaded protein was checked by expression of b-isoform of actin. A blot representative of three
independent experiments with analogous results is shown. Bar plots represent band intensity of GLUT1 and GLUT3 normalized to b-actin
and reported as mean  SEM of three independent experiments, -fold change over control. The effect of SK1 expression was statistically
significant by Student’s t-test, *P < 0.05. (D) MCT1 and MCT4 expression by WB. Equally loaded protein was checked by expression of b-
isoform of actin. A blot representative of three independent experiments with analogous results is shown. Bar plots represent the
densitometric analysis of at least three independent experiments. Data are the mean  SEM and are reported as protein expression
normalized to b-actin, -fold change over control (set as 1). The effect of SK1 expression was statistically significant by Student’s t-test,
*P < 0.05.
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SK1 protein level and activity in ovarian cancer cells is
causative of high glycolytic rates and decreased oxida-
tive metabolism under aerobic conditions. Therefore,
SK1 positively regulates glycolysis for bioenergetic
demand.
3.5. Dysregulation of other metabolic pathways
in SK1-expressing ovarian cancer cells
High-proliferating cancer cells must not only generate
enough energy to support cell replication, but also
Fig. 3. SK1 expression reduces oxidative metabolism in A2780 ovarian cancer cells. A2780 mock and SK1 cells were cultured in growing
medium or serum-starved for 24 h. (A) Box plots: the relative concentration levels of the indicated metabolites in each group were
calculated by integrating the signal area in the respective 1H-NMR spectra. Changes in metabolite levels caused by SK1 expression were
statistically significant by paired Wilcoxon test, *P < 0.05. (B) Respiration of [14C]-glucose was evaluated as [14C]-CO2 release. The reduction
in [14C]-CO2 release caused by SK1 expression was statistically significant by Student’s t-test, *P < 0.05.
526 Molecular Oncology 11 (2017) 517–533 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
SK1 determines the metabolic phenotype in cancer C. Bernacchioni et al.
satisfy the anabolic demands of macromolecular
biosynthesis and maintain cellular redox homeostasis.
The variation observed in some metabolites or
enzymes whose levels changed significantly in SK1-
expressing cells is discussed below in the context of the
implicated pathways. Nevertheless, the interpretation
of their role remains at the level of hypothesis due to
the lack of information on the concentration of more
intermediates of the identified pathways. The pentose
phosphate pathway (PPP) is a major glucose catabolic
pathway that supplies anabolism-linking glucose to the
biosynthesis of the nucleotide precursor ribose and to
NADPH production. This latter process is essential
for both antioxidant defense and reductive biosynthe-
sis, such as fatty acid synthesis. PPP is reported to be
augmented by oncoproteins (Jiang et al., 2014). The
first enzyme in the PPP pathway is glucose 6-phos-
phate dehydrogenase (G6PDH), which catalyzes the
dehydrogenation of glucose 6-phosphate through an
irreversible, rate-limiting reaction. The results of WB
analysis, shown in Fig. 4A, demonstrate that SK1
expression determined an increase in G6PDH expres-
sion levels in ovarian cancer.
Glycolysis and PPP are two metabolic pathways that
are tightly connected and cooperatively regulate glu-
cose uptake and metabolism. SK1 expression was suffi-
cient to modulate both pathways in ovarian cancer
cells, providing further experimental support to the
significant reduction in intracellular glucose 6-phos-
phate levels (Fig. 2A).
An increased SK1-induced biosynthesis of nucleo-
tides is consistent with the increased levels of inosine
monophosphate (IMP), as shown in Fig. 4B. IMP rep-
resents the final product of purine biosynthesis: both
adenine and guanine derive from IMP.
It is known that a small fraction of glucose (≤ 5%)
is used in the hexosamine biosynthesis pathway (Van-
der Heiden et al., 2009). This metabolic route gener-
ates, as ultimate product, the nucleotide sugar uridine
diphosphate N-acetylglucosamine (UDP-GlcNAc).
Several key metabolites, including glucose 6-phosphate
from glycolysis and uridine from nucleotide biosynthe-
sis, are required for UDP-GlcNAc formation. Interest-
ingly, greater increases in UDP-GlcNAc levels
correlate with higher grades of tumor development
(Chaiyawat et al., 2014). In this regard, our metabolo-
mic analysis showed a clear rise in UDP-GlcNAc
levels in SK1-expressing cells (Fig. 4B).
Higher levels of creatine were found in SK1-expres-
sing cells (Fig. 4B). Creatine and phosphocreatine pro-
vide an intracellular, high-energy phosphate buffering
system, essential to maintain ATP levels in tissues with
high-energy demands. Although creatine synthesis
from arginine and glycine primarily takes place in the
kidney and liver, the expression of the enzymes
involved in its synthesis has been reported for different
types of cancer (Bera et al., 2008). Therefore, the high
Fig. 4. SK1-induced metabolic changes in A2780 ovarian cancer
cells. A2780 mock and SK1 cells were cultured in growing medium
or serum-starved for 24 h. (A) G6PDH expression by WB. Equally
loaded protein was checked by expression of b-isoform of actin. A
blot representative of three independent experiments with
analogous results is shown. The bar plot represents band intensity
of G6PDH normalized to b-actin and reported as mean  SEM of
three independent experiments, -fold change over control. The
effect of SK1 expression was statistically significant by Student’s t-
test, *P < 0.05. (B) Box plots: the relative concentration levels of
the indicated metabolites in each group were calculated by
integrating the signal area in the respective 1H-NMR spectra.
Changes in metabolite levels caused by SK1 expression were
statistically significant by paired Wilcoxon test, *P < 0.05.
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creatine levels observed in SK1-expressing ovarian can-
cer cells could depend on its increased biosynthesis. In
accordance with this hypothesis, glycine and arginine
levels are also significantly augmented in consequence
of SK1 expression (Figs 2A and 4B).
Moreover, asparagine, well-known important regula-
tor of cancer cell amino acid homeostasis, anabolic
metabolism, and proliferation (Krall et al., 2016), is
found augmented in consequence of SK1 expression in
ovarian cancer cells (Fig. 4B).
3.6. Activated signaling pathways in SK1-
expressing ovarian cancer cells
S1P is widely reported to act through an inside-out
signaling mechanism that occurs via export of intracel-
lularly generated S1P and ligation to S1PR. We deter-
mined the expression levels of S1PR by mRNA
relative quantification through real-time RT-PCR
analysis. Both control and SK1-expressing A2780 cells
express four out of five S1PR, S1P2, S1P3, S1P4, and
S1P5, while S1P1 expression was not detectable in any
experimental condition (Fig. 5A). Independently from
the culture conditions, the expression of SK1 caused a
strong induction of S1P3 expression, the other receptor
isoforms being unaltered, thus suggesting the existence
of an amplification loop between SK1 and S1P3,
already observed in TGF-b-treated myoblasts (Cencetti
et al., 2010) and in breast cancer cells (Long et al.,
2010). To test this hypothesis, we treated SK1-expres-
sing cells with VPC23019 (1 lM for 24 h), a specific
antagonist for S1P1 and S1P3. In this cellular context,
VPC23019 should antagonize only S1P3, with S1P1 not
being expressed. Under these experimental conditions,
none of the metabolite level changes measured by
NMR resulted meaningful (data not shown), suggest-
ing that this receptor subtype does not play a role in
the metabolic switch induced by SK1. Nevertheless,
there was a clear contribution from exogenously added
S1P on A2780 cell metabolism. Indeed, S1P adminis-
tration (1 lM for 24 h) to mock control A2780 cells
induced a significant increase in lactate levels and a
Fig. 5. SK1-induced pathways in A2780 ovarian cancer cells. Ovarian mock and SK1 A2780 cells were cultured in growing medium or
serum-starved for 24 h. (A) Quantitative mRNA analysis by real-time PCR in total extracted RNA. S1PR mRNA quantitation was based on
the 2ΔΔCT method, using S1P2, S1P3, S1P4, or S1P5 of the mock-transfected specimen as calibrator. nd, not detected. The increase in
S1P3 expression in SK1-expressing cells was statistically significant by Student’s t-test, *P < 0.05. (B) Cell lysates were analyzed by WB
using specific anti-phospho-Akt, anti-pan Akt, anti-phospho-ERK1/2, and anti-pan ERK1/2 antibodies. Blots representative of at least three
independent experiments are shown. Bar plots represent densitometric quantification of phosphorylated proteins normalized to their total
content and reported as mean  SEM of three independent experiments, -fold change over control set as 1. The effect of SK1 expression
was statistically significant by Student’s t-test, *P < 0.05.
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decrease in glucose 6-phosphate levels, while concen-
tration changes in TCA intermediates were not signifi-
cant (Fig. S6). It is tempting to speculate that acute
S1P administration might not be sufficient to sustain a
metabolic switch, being not able to mimic continuous
S1P production following SK1 expression. Moreover,
the topology of endogenously produced S1P could be
differently regulated with respect to exogenously added
S1P (Nincheri et al., 2010). However, additional future
studies are required to deeply characterize the role of
S1PR involvement in the SK1-induced metabolic shift.
Among the signaling pathways correlated with
S1PR activation, we analyzed the activation state of
two key signal transduction pathways, Akt and
ERK1/2. The WB shown in Fig. 5B indicates that a
sustained activation of Akt signaling is present in
SK1-expressing cells independently from the presence
of mitogens in the culture medium, while ERK1/2
phosphorylation is unaffected.
Several signaling cascades are deregulated in cancer
cells and appear to control altered metabolism, apop-
tosis, and other phenotypic features of cancer cells
(Giancotti, 2014). In this context, Akt has been
reported to play a key role in the metabolic conversion
of cancer cells toward aerobic glycolysis in different
ways. Indeed, Akt signaling has been shown to be
implicated in the upregulation of glucose transporters
as well as multiple glycolytic enzymes (Robey and
Hay, 2009), thus increasing glucose import and con-
sumption by cancer cells. The activation of Akt is
often detected following membrane receptor(s) engage-
ment and is implicated in different S1PR downstream
signaling (Blaho and Hla, 2014), suggesting that the
here observed increased phosphorylation of Akt may
rely on the engagement of S1PR through SK1-derived
S1P, according to the well-established inside-out mech-
anism of action of the bioactive sphingolipid (Takabe
et al., 2008).
4. Conclusions
Here, we demonstrate that SK1 plays a crucial role in
the metabolic shift toward an aberrant metabolic phe-
notype driving ovarian cancer cells toward aerobic gly-
colysis and more sustained macromolecule biosynthesis
(Fig. 6). These findings rely on original and innovative
combination of untargeted NMR metabolomics and
targeted biochemical methodologies. All the observed
metabolic features induced by SK1 expression in ovar-
ian cancer cells were found to be independent from the
culture conditions (growing or serum starvation), indi-
cating that SK1 is sufficient to induce the specific
metabolic phenotype.
In accordance with our findings, it has been recently
reported that S1P promotes erythrocyte glycolysis for
adaptation to high-altitude hypoxia (Sun et al., 2016),
thus providing novel mechanistic insights on how
increased glycolytic fluxes might be related to SK1-
mediated generation of S1P. Although this newly dis-
covered mechanism of action of S1P could be
restricted to mature erythrocytes as they store highest
amounts of S1P, it confirms the relevance of this sig-
naling pathway in the regulation of metabolic pro-
cesses such as glycolysis.
A suggested role of SK1 in aerobic glycolysis comes
from studies on prostate LNCaP cancer cells. Treat-
ment of LNCaP with the SKs pan-inhibitor SKi
affects the levels of few intermediates of the glycolytic
pathway and augments the proteasomal activity with
consequent degradation of several proteins, including
SK1 (Watson et al., 2013). However, recent studies
have shown a number of important off-target effects
of SKi (Pitman et al., 2016). The present study pro-
vides the first direct evidence of the role of SK1 in
cancer cell metabolism reprogramming. The untargeted
metabolic profiling provides a general picture of the
complex metabolic network driving to cancer meta-
bolic adaptation and development, which goes beyond
the regulation of the glycolysis. The SK1-induced
alteration in a number of metabolic processes is
demonstrated by complementary biochemical assays.
The high glycolytic rate, with increased levels of
lactate along with increased expression of the
proton/monocarboxylate symporter MCT1, is paral-
leled by decreased oxidative metabolism, with
Fig. 6. Metabolic shift induced by SK1 expression in A2780 ovarian
cancer cells. Red arrows represent augmented fluxes, while cyan
arrows indicate diminished processes in consequence of SK1
expression. Metabolite/protein levels and metabolic pathways are
shown in red or cyan if they are, respectively, augmented or
decreased in SK1-expressing ovarian cancer cells.
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accumulation of intermediates of the TCA and reduc-
tion in CO2 production. Additionally, SK1-expressing
A2780 ovarian cancer cells showed a significant
increase in glucose uptake associated with GLUT3
transporter upregulation. SK1 expression caused also a
strong induction of S1P3 expression as well as a sus-
tained activation of Akt signaling pathway.
The identification of SK1 as a key regulator of can-
cer metabolic phenotype opens new routes for the
development of therapies targeting the metabolic
adaptability accompanying the oncogenic process.
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Fig. S1. A2780 cells were stably transfected with the
empty expression vector (mock) or with pcDNA3-
hSK1WT plasmid (SK1).
Fig. S2. Score plot of unsupervised PCA analysis of
mock- and SK1-cell lysates: PC1, PC2 and PC3.
Fig. S3. Bar plot of -Log2 (FC) of the analyzed
metabolites.
Fig. S4. Mock and SK1-expressing cells were serum-
starved for 24 h before the cells were harvested and
then subjected to Sph and Cer analysis.
Fig. S5. (A) Bar plots of Log2 (FC) of the metabo-
lites related to glycolysis and to TCA cycle (left and
right panel, respectively). Metabolites with Log2
(FC) negative values have lower concentration in
SK1 + VPC96091 samples with respect to SK1
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samples. Metabolites with Log2 (FC) positive values
have higher concentration in SK1 + VPC96091 sam-
ples with respect to SK1 samples. Metabolites whose
concentration is significantly different (P-value < 0.05,
by Paired Wilcoxon test) in SK1 + VPC96091 cells
with respect to SK1 cells are marked with *. (B)
Box plots: relative concentration levels of the indicated
metabolites in each group were calculated by integrat-
ing the signal area in the 1H NMR spectra. Metabo-
lites whose concentration is significantly different (P-
value < 0.05, by Paired Wilcoxon test) in SK1 cells
with respect to mock cells are marked with # while
metabolites whose concentration is significantly differ-
ent (P-value < 0.05, by Paired Wilcoxon test) in
SK1 + VPC96091 cells with respect to SK1 cells are
marked with *.
Fig. S6. Box plots: relative concentration levels of the
indicated metabolites in each group were calculated by
integrating the signal area in the 1H NMR spectra.
Table S1. Analyzed metabolites.
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